title: [Case of scleroderma with rapid progressive glomerulonephritis associated with both MPO-ANCA and anti-GBM antibodies].
abstract: A 66-year-old male with scleroderma developed rapidly progressive glomerulonephritis (RPGN). Renal pathology revealed crescentic glomerulonephritis with interstitial inflammation and fibrosis. Immunofluorescent micrography showed linear deposition of IgG along the glomerular capillary wall. Both anti-glomerular basement membrane antibody (anti-GBM Ab), and myeloperoxidase-antineutrophil cytoplasmic antibody (MPO-ANCA) were detected by an enzyme-linked immunosorbent assay (ELISA). These findings were compatible with ANCA-related vasculitis and anti-GBM Ab nephritis. Laboratory findings showed rapid elevation of the serum creatinine level (5.9 mg/dL), and a high titer of MPO-ANCA (530 EU) and anti-GBM Ab (21 EU). He was started on methylprednisolone pulse therapy and temporary hemodialysis. Since the immunosuppressive therapy lowered both antibody titers steadily and improved renal function, hemodialysis was discontinued 4 weeks after the therapy. It has been reported that some scleroderma patients developed rapid progressive glomerulonephritis due to ANCA-associated vasculitis in addition to the typical scleroderma renal crisis. There have been few reports of a scleroderma patient associated with RPGN, in whom both MPO-ANCA and anti GBM antibodies were detected.
authors.affiliation: Division of Nephrology, Osaka Rosai Hospital, Osaka, Japan.
authors.forename: Tomoko
authors.initials: T
authors.lastname: Namba
authors.forename: Masaki
authors.initials: M
authors.lastname: Hatanaka
authors.forename: Atsushi
authors.initials: A
authors.lastname: Takahashi
authors.forename: Masanobu
authors.initials: M
authors.lastname: Takeji
authors.forename: Ken
authors.initials: K
authors.lastname: Takahara
authors.forename: Takashi
authors.initials: T
authors.lastname: Uzu
authors.forename: Atsushi
authors.initials: A
authors.lastname: Yamauchi
mesh_terms: D000368:Aged; D019268:Antibodies, Antineutrophil Cytoplasmic / Q000032:analysis*; D001323:Autoantibodies / Q000032:analysis*; D015415:Biomarkers / Q000032:analysis; D018450:Disease Progression; D050533:Glomerular Basement Membrane / Q000276:immunology*; D005921:Glomerulonephritis / Q000150:complications* / Q000175:diagnosis / Q000473:pathology / Q000628:therapy; D006801:Humans; D007074:Immunoglobulin G / Q000032:analysis; D008297:Male; D008775:Methylprednisolone / Q000008:administration & dosage; D009195:Peroxidase / Q000276:immunology*; D011239:Prednisolone / Q000008:administration & dosage; D020551:Pulse Therapy, Drug; D006435:Renal Dialysis; D012595:Scleroderma, Systemic / Q000150:complications* / Q000175:diagnosis
chemical_list: D019268:Antibodies, Antineutrophil Cytoplasmic; D001323:Autoantibodies; D015415:Biomarkers; D007074:Immunoglobulin G; D011239:Prednisolone; D009195:Peroxidase; D008775:Methylprednisolone